SCHOFIELD, Wis., Aug. 5, 2014 /PRNewswire/ -- PuraMed
BioScience®, Inc., (OTCPink: PMBS), a researcher,
developer, and marketer of over-the-counter (OTC) medicinal and
healthcare products, announced today that it plans to begin testing
of a new hemp-based epilepsy medication in the fourth quarter of
2014.
"As we looked at the similarities between migraine and epilepsy
the treatment path became obvious," said Russell Mitchell, CEO and Chairman of PuraMed
BioScience. "Epilepsy and migraine seem to be triggered by the same
coritcal spreading depression (CSD) in the brain; the difference is
the rate of reaction. This may be why many migraineurs are
prescribed epileptic medications."
According to an article in Seizure, the prevalence of
migraine in people who experience epilepsy is 8.4 to 20 percent. In
addition to migraine, an estimated 64 percent of epilepsy sufferers
also experience seizure-related (ictal) headaches: 20 percent
experience headache prior to the seizure (pre-ictal) and 44 percent
experience headache after the seizure (post-ictal).
The third most common neurological disorder in the US, epilepsy
affects approximately 2.7 million people, with children and older
adults being most susceptible. The condition also causes up to
50,000 sudden deaths each year.
Epilepsy affects veterans wounded in combat. According to
Citizens United to Cure Epilepsy, approximately 22 percent of the
440,000 military service men and women who experienced traumatic
brain injury are expected to develop post-traumatic epilepsy.
"An epilepsy medication is a natural extension to our product
line," said Mitchell. "We have developed a formula, now we will
begin the setting up the trials. We have been approached by key
researchers who have expressed interest in working with us on
CBD-based products.
"Standardization is key to creating a quality sublingual
formula," said Mitchell. " Sublingual delivery offers the distinct
advantages of faster delivery and efficiency while avoiding the
"first pass effect" that often degrades oral medications. Our goal
is to build medicines that withstand scientific scrutiny and
perform well in double-blind, placebo controlled clinical trials.
We believe that the efficacy of our formulations will be proven by
scientific trials. This type of testing lends credibility to our
line of natural medications which often work faster, more
effectively, and have fewer side effects than their chemical-based
counterparts."
Currently, PuraMed BioScience is rebranding its flagship
product, LipiGesic M, as MigraPure.
About MigraPure
MigraPure uses the same sublingual feverfew and ginger formula
that was clinically tested as LipiGesic M. The flavor of this
homeopathic, all-natural, over-the-counter migraine headache pain
relief medication has been enhanced, but the active ingredients
that stop disabling migraine pain and associated symptoms quickly,
is the same. MigraPure's feverfew and ginger gel is non-drowsy and
non-habit forming. MigraPure is not associated with rebound
headaches. MigraPure has an excellent safety profile and has no
reported drug interactions.
About PuraMed BioScience, Inc.
PuraMed BioScience engages in the research, development, and
marketing of non-prescription medicinal and healthcare products. In
addition to rebranding LipiGesic M to MigraPure, PuraMed BioScience
plans to launch additional cannabinoid-enhanced, anti-inflammatory,
and anxiolytic products as it moves forward in the development of
its cannabinoid product line.
Forward-Looking Statements
This news release contains forward-looking statements regarding
PuraMed BioScience, Inc., and its future business plans, which
statements involve known and unknown risks and uncertainties. Such
risks and uncertainties may cause actual results and future
achievements of PuraMed BioScience to be materially different from
those implied by these forward-looking statements. PuraMed
BioScience has and undertakes no obligation to provide public
updates and revisions to these forward-looking statements to
reflect any changes in its expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and
CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com
SOURCE PuraMed BioScience, Inc.